Patents by Inventor Tom Vink

Tom Vink has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heterodimeric antibody Fc-containing proteins and methods for production thereof
    Patent number: 11866514
    Abstract: Novel heterodimeric antibody-Fc-containing proteins, such as bispecific antibodies, and novel methods for producing such proteins.
    Type: Grant
    Filed: January 30, 2020
    Date of Patent: January 9, 2024
    Assignee: GENMAB A/S
    Inventors: Aran Frank Labrijn, Joyce I. Meesters, Ewald T. J. Van Den Bremer, Joost J. Neijssen, Patrick Van Berkel, Bart De Goeij, Tom Vink, Jan Van De Winkel, Janine Schuurman, Paul Parren
  • HUMAN ANTIBODIES AGAINST TISSUE FACTOR AND METHODS OF USE THEREOF
    Publication number: 20230416403
    Abstract: Isolated human monoclonal antibodies which bind to human TF and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, and therapeutic and diagnostic methods for using the antibodies.
    Type: Application
    Filed: December 6, 2022
    Publication date: December 28, 2023
    Inventors: Sandra VERPLOEGEN, David P. E. SATIJN, Rene M. A. HOET, Paul PARREN, Jan VAN DE WINKEL, Vibeke Miller BREINHOLT, Eva EHRNROOTH, Ole BAADSGAARD, Tom VINK, Willem Karel BLEEKER, Mischa HOUTKAMP, Maroeska OUDSHOORN, Rob N. DE JONG
  • Agents, Uses and Methods for the Treatment of Synucleinopathy
    Publication number: 20230312693
    Abstract: The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy.
    Type: Application
    Filed: November 22, 2022
    Publication date: October 5, 2023
    Inventors: Pekka KALLUNKI, Karina FOG, Louise Buur VESTERAGER, Ann-Louise BERGSTRÔM, Florence SOTTY, David SATIJN, Edward VAN DEN BRINK, Paul PARREN, Rik RADEMAKER, Tom VINK, Ibrahim John MALIK, Liliana Christina Pereira MONTEZINHO, Jeffrey B STAVENHAGEN
  • MULTISPECIFIC ANTIGEN-BINDING MOLECULE WITH IMPROVED INTERNALIZATION CHARACTERISTICS
    Publication number: 20230076417
    Abstract: The present invention relates to a multispecific antigen-binding molecule comprising a first antigen-binding domain and a second antigen-binding domain. The first domain specifically binds a target molecule (T), and the second domain specifically binds an internalizing effector protein (E), the second antigen-binding domain having a dissociation constant (KD) with E of between 10?9 and 10?8 M. The multispecific antigen-binding molecule is useful in a method for treating and/or preventing a cancer.
    Type: Application
    Filed: April 6, 2022
    Publication date: March 9, 2023
    Inventors: Bart DE GOEIJ, Joost MELIS, Tom VINK, Hendrik TEN NAPEL, Esther BREIJ, David SATIJN, Paul PARREN
  • Agents, uses and methods for the treatment of synucleinopathy
    Patent number: 11542323
    Abstract: The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy.
    Type: Grant
    Filed: November 3, 2020
    Date of Patent: January 3, 2023
    Assignee: H. Lundbeck A/S
    Inventors: Pekka Kallunki, Karina Fog, Louise Buur Vesterager, Ann-Louise Bergstrôm, Florence Sotty, David Satijn, Edward Van Den Brink, Paul Parren, Rik Rademaker, Tom Vink, Ibrahim John Malik, Liliana Christina Pereira Montezinho, Jeffrey B Stavenhagen
  • RECOMBINANT MONOVALENT ANTIBODIES AND METHODS FOR PRODUCTION THEREOF
    Publication number: 20220396629
    Abstract: The present invention provides monovalent antibodies with a long half-life when administered in vivo, methods of making such monovalent antibodies, pharmaceutical compositions comprising such antibodies, and uses of the monovalent antibodies.
    Type: Application
    Filed: May 26, 2022
    Publication date: December 15, 2022
    Inventors: Paul PARREN, Janine Schuurman, Tom Vink, Willem Karel Bleeker, Jan Van De Winkel, Patrick Van Berkel, Frank Beurskens
  • Agents, uses and methods for the treatment of synucleinopathy
    Patent number: 11524995
    Abstract: The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy.
    Type: Grant
    Filed: June 8, 2020
    Date of Patent: December 13, 2022
    Assignee: H. Lundbeck A/S
    Inventors: Pekka Kallunki, Karina Fog, Louise Buur Vesterager, Ann-Louise Bergström, Florence Sotty, David Satijn, Edward van den Brink, Paul Parren, Rik Rademaker, Tom Vink, Ibrahim John Malik, Liliana Christina Pereira Montezinho, Jeffrey B. Stavenhagen
  • Agents, uses and methods for the treatment of synucleinopathy
    Patent number: 11421024
    Abstract: The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy.
    Type: Grant
    Filed: August 27, 2020
    Date of Patent: August 23, 2022
    Assignee: H. Lundbeck A/S
    Inventors: Pekka Kallunki, Karina Fog, Louise Buur Vesterager, Ann-Louise Bergstrôm, Florence Sotty, David Satijn, Edward Van Den Brink, Paul Parren, Rik Rademaker, Tom Vink, Ibrahim John Malik, Liliana Christina Pereira Montezinho
  • ANTIBODIES AGAINST HUMAN CD38
    Publication number: 20220204636
    Abstract: Isolated monoclonal antibodies which bind to human CD38 and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies.
    Type: Application
    Filed: December 14, 2021
    Publication date: June 30, 2022
    Inventors: Michel DE WEERS, Tim WALSETH, Jan VAN DE WINKEL, Tom VINK, Paul PARREN
  • POTENCY ASSAYS FOR ANTIBODY DRUG SUBSTANCE BINDING TO AN FC RECEPTOR
    Publication number: 20220177585
    Abstract: The invention relates to a method of characterizing an antibody, which method is suitable as a potency assay for batch release of a pharmaceutical composition comprising an antibody, specifically for use when applying for marketing authorization for said pharmaceutical composition. The assay provided is a method for determining the potency of a drug product comprising an FcR binding peptide, wherein at least one mechanism of action of the FcR binding peptide of the drug product is mediated through the binding of the FcR binding peptide of the drug product to a Fc receptor, wherein said method comprises determining the binding of the FcR binding peptide of the drug product to an Fc receptor.
    Type: Application
    Filed: June 16, 2021
    Publication date: June 9, 2022
    Inventors: Catharina Emanuele GERARDA HAVENITH, Tom VINK, Patrick VAN BERKEL, Paul PARREN
  • Antibodies against human CD38
    Patent number: 11230604
    Abstract: Isolated monoclonal antibodies which bind to human CD38 and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies.
    Type: Grant
    Filed: March 1, 2018
    Date of Patent: January 25, 2022
    Assignee: GENMAB A/S
    Inventors: Michel De Weers, Tim Walseth, Jan Van De Winkel, Tom Vink, Paul Parren
  • HUMAN ANTIBODIES AGAINST TISSUE FACTOR AND METHODS OF USE THEREOF
    Publication number: 20210171657
    Abstract: Isolated human monoclonal antibodies which bind to human TF and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, and therapeutic and diagnostic methods for using the antibodies.
    Type: Application
    Filed: May 21, 2020
    Publication date: June 10, 2021
    Applicants: GENMAB A/S, GENMAB A/S
    Inventors: Sandra VERPLOEGEN, David P.E. SATIJN, Rene M.A. HOET, Paul PARREN, Jan VAN DE WINKEL, Vibeke Miller BREINHOLT, Eva EHRNROOTH, Ole BAADSGAARD, D.M.Sc., Tom VINK, Willem Karel BLEEKER, Mischa HOUTKAMP, Maroeska OUDSHOORN, Rob N. DE JONG
  • AGENTS, USES AND METHODS FOR THE TREATMENT OF SYNUCLEINOPATHY
    Publication number: 20210147522
    Abstract: The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy.
    Type: Application
    Filed: August 27, 2020
    Publication date: May 20, 2021
    Inventors: Pekka KALLUNKI, Karina FOG, Louise Buur VESTERAGER, Ann-Louise BERGSTRÔM, Florence SOTTY, David SATIJN, Edward VAN DEN BRINK, Paul PARREN, Rik RADEMAKER, Tom VINK, Ibrahim John MALIK, Liliana Christina Pereira MONTEZINHO
  • AGENTS, USES AND METHODS FOR THE TREATMENT OF SYNUCLEINOPATHY
    Publication number: 20210061892
    Abstract: The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy.
    Type: Application
    Filed: November 3, 2020
    Publication date: March 4, 2021
    Inventors: Pekka KALLUNKI, Karina FOG, Louise Buur VESTERAGER, Ann-Louise BERGSTRÔM, Florence SOTTY, David SATIJN, Edward VAN DEN BRINK, Paul PARREN, Rik RADEMAKER, Tom VINK, Ibrahim John MALIK, Liliana Christina Pereira MONTEZINHO
  • STABLE IgG4 ANTIBODIES
    Publication number: 20210061919
    Abstract: The present invention relates to novel stabilized IgG4 antibodies, to methods of producing such antibodies and to uses of such antibodies as a medicament. In a main aspect, the invention relates to a stabilized IgG4 antibody, comprising a heavy chain and a light chain, wherein said heavy chain comprises a human IgG4 constant region having a substitution of the Arg residue at position (409), the Phe residue at position (405) or the Lys residue at position (370).
    Type: Application
    Filed: July 15, 2020
    Publication date: March 4, 2021
    Applicant: GENMAB A/S
    Inventors: Jan VAN DE WINKEL, Tom VINK, Janine SCHUURMAN, Paul PARREN, Rob AALBERSE, Marijn VAN DER NEUT KOLFSCHOTEN
  • AGENTS, USES AND METHODS FOR THE TREATMENT OF SYNUCLEINOPATHY
    Publication number: 20210054057
    Abstract: The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy.
    Type: Application
    Filed: June 8, 2020
    Publication date: February 25, 2021
    Inventors: Pekka KALLUNKI, Karina FOG, Louise Buur VESTERAGER, Ann-Louise BERGSTRÔM, Florence SOTTY, David SATIJN, Edward VAN DEN BRINK, Paul PARREN, Rik RADEMAKER, Tom VINK, Ibrahim John MALIK, Liliana Christina Pereira MONTEZINHO
  • Bispecific antibodies and methods for production thereof
    Patent number: 10906991
    Abstract: The invention relates to an ex vivo method for the generation of a bispecific antibody, comprising the steps of: a) providing a first antibody having a first binding specificity, wherein said first antibody comprises an IgG4-like CH3 region, b) providing a second antibody having a second binding specificity which differs from said first binding specificity, wherein said second antibody comprises an IgG4-like CH3 region, c) incubating said first and second antibodies together under reducing conditions which allow the cysteines in the core hinge region to undergo disulfide-bond isomerization, and d) obtaining a bispecific antibody. The invention furthermore relates to bispecific antibodies obtainable by the method of the invention.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: February 2, 2021
    Assignee: GENMAB A/S
    Inventors: Janine Schuurman, Tom Vink, Jan Van De Winkel, Aran Frank Labrijn, Rob Aalberse, Marijn Van Der Neut Kolfschote, Paul Parren
  • Agents, uses and methods for the treatment of synucleinopathy
    Patent number: 10800836
    Abstract: The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy.
    Type: Grant
    Filed: July 12, 2016
    Date of Patent: October 13, 2020
    Assignee: H. Lundbeck A/S
    Inventors: Pekka Kallunki, Karina Fog, Louise Buur Vesterager, Ann-Louise Bergstrôm, Florence Sotty, David Satijn, Edward van den Brink, Paul Parren, Rik Rademaker, Tom Vink, Ibrahim John Malik, Liliana Christina Pereira Montezinho
  • Stable IgG4 antibodies
    Patent number: 10752695
    Abstract: The present invention relates to novel stabilized IgG4 antibodies, to methods of producing such antibodies and to uses of such antibodies as a medicament. In a main aspect, the invention relates to a stabilized IgG4 antibody, comprising a heavy chain and a light chain, wherein said heavy chain comprises a human IgG4 constant region having a substitution of the Arg residue at position (409), the Phe residue at position (405) or the Lys residue at position (370).
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: August 25, 2020
    Assignee: Genmab A/S
    Inventors: Jan Van De Winkel, Tom Vink, Janine Schuurman, Paul Parren, Rob Aalberse, Marijn Van Der Neut Kolfschoten
  • HETERODIMERIC ANTIBODY FC-CONTAINING PROTEINS AND METHODS FOR PRODUCTION THEREOF
    Publication number: 20200262932
    Abstract: Novel heterodimeric antibody-Fc-containing proteins, such as bispecific antibodies, and novel methods for producing such proteins
    Type: Application
    Filed: January 30, 2020
    Publication date: August 20, 2020
    Inventors: Aran Frank LABRIJN, Joyce I. MEESTERS, Ewald T. J. VAN DEN BREMER, Joost J. NEIJSSEN, Patrick VAN BERKEL, Bart DE GOEIJ, Tom VINK, Jan VAN DE WINKEL, Janine SCHUURMAN, Paul PARREN